Cookies & Privacy

We use essential cookies to make our site work. With your permission, we’ll also use analytics and marketing cookies to improve your experience. You can change your choice anytime.

See our Privacy Policy for details.

Manage preferences
Cookie preferences
Back to Industry News
Medtech

Investors Use Derivatives to Navigate US Corporate Bonds

Summary generated with AI, editor-reviewed
Heartspace News Desk
Source: Bloomberg.com

Key takeaways

  • corporate bond market are experiencing substantial returns from interest and principal payments
  • This influx of capital is being reinvested at a pace so rapid that it is generating demand which corporate issuers are finding difficult to meet
  • Data compiled by Bloomberg indicates that blue-chip companies issued over $1 trillion in bonds through August of this year
Investors in the U.S. corporate bond market are experiencing substantial returns from interest and principal payments. This influx of capital is being reinvested at a pace so rapid that it is generating demand which corporate issuers are finding difficult to meet. Data compiled by Bloomberg indicates that blue-chip companies issued over $1 trillion in bonds through August of this year. Despite this considerable issuance volume, analysis from BNP Paribas suggests that money managers received an even larger amount from their existing bond investments during the same period. This market dynamic highlights that the majority of this capital is being redeployed into corporate bonds. Consequently, the rate at which investors generate and reinvest capital is currently exceeding the supply of new debt offerings from corporations.

Related Topics

corporate bondsderivativesinvestor returnscapital reinvestmentUS marketfinancial instruments

Share Your Thoughts

(0 comments)

Be the first to share your thoughts on this article!

Stay Updated

Create alertsRead original